Internal Reference Number: FOI_7431
Date Request Received: 15/09/2023 00:00:00
Date Request Replied To: 06/10/2023 00:00:00
This response was sent via: By Email
Request Summary: intra-vitreal injections or implants
Request Category: Companies
| Question Number 1: How many of the following intra-vitreal injections/implants has your trust administered in the four-month period from May to August 2023: 鈥� Aflibercept 鈥� Bevacizumab - Avastin 鈥� Bevacizumab - Biosimilar 鈥� Brolucizumab 鈥� Dexamethasone 鈥� Faricimab 鈥� Fluocinolone acetonide 鈥� Ranibizumab - Lucentis (pre-filled syringes) 鈥� Ranibizumab - Lucentis (vials) 鈥� Ranibizumab 鈥� Ongavia | |
| Answer To Question 1: Aflibercept 1289 Bevacizumab - Avastin <5 Bevacizumab - Biosimilar 0 Brolucizumab 0 Dexamethasone 10 Faricimab 678 Fluocinolone acetonide 0 Ranibizumab - Lucentis (pre-filled syringes) 10 Ranibizumab - Lucentis (vials) 0 Ranibizumab 鈥� Ongavia 0 | |
| Question Number 2: Please provide the number of injections/implants by eye condition for the four-month period from May to August 2023: See table attached | |
| Answer To Question 2: Please see attached table. To accompany this answer to question 2 please also see the documents listed below:  7431 Questionnaire Q2.pdf | |
| Please see Attachments: | |
| To return to the list of all the FOI requests please click here | |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of 看片软件 Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
